eligibility_summary
Age ≥18, stage IV pancreatic adenocarcinoma, measurable disease, ECOG 0–1, biopsiable lesion, adequate labs, QTcF <450/460. Dose escalation: eligible for gem+nab-paclitaxel, expansion: prior 5FU-based therapy. Key exclusions: prior gem+nab-paclitaxel, significant neuropathy, untreated CNS mets, pregnant/breastfeeding, active infection/HIV/HBV/HCV, cancer, transplants, ILD/pneumonitis, major cardiac disease/surgery. Atezolizumab cohorts: autoimmune disease, immunosuppression, live vaccine.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06182072 tests ProAgio (ACT50), an anti-αvβ3 integrin protein cytotoxin, alone and combined with gemcitabine/nab‑paclitaxel (G‑nP) ± atezolizumab in metastatic PDAC. Mechanisms/types: • ProAgio: engineered biologic that binds integrin αvβ3 and induces apoptosis in αvβ3‑expressing cells, aims to remodel the tumor microenvironment. • Gemcitabine: antimetabolite nucleoside analog inhibiting DNA synthesis (cytotoxic chemotherapy). • Nab‑paclitaxel: albumin‑bound paclitaxel, a microtubule‑stabilizing cytotoxic that causes mitotic arrest. • Atezolizumab: anti‑PD‑L1 monoclonal antibody (immune checkpoint inhibitor) restoring T‑cell activity. Targets/pathways: αvβ3 integrin–positive stromal and endothelial (and some tumor) cells, DNA replication in proliferating tumor cells, microtubule dynamics, PD‑1/PD‑L1 axis on tumor/immune cells. Phase I/Ib focuses on safety, PK/PD, and RP2D.